National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$54.00
add to cart

Rights & Permissions

Related Titles

topleft topright

Environmental Medicine: Integrating a Missing Element into Medical Education (1995)
Institute of Medicine (IOM)

Citation Manager

. "Case Study 30: Aldicarb Poisoning: A Case Report with Prolonged Cholinesterase Inhibition and Improvement After Pralidoxime Therapy." Environmental Medicine: Integrating a Missing Element into Medical Education. Washington, DC: The National Academies Press, 1995.

Please select a format:

BibTeX EndNote RefMan


Page
559
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Environmental Medicine: Integrating a Missing Element into Medical Education

cause of abundant secretions. His wife and child were not affected. He denied previous medical problems or taking medications. However, over the previous 6 months he had had several similar episodes, one of which required emergency treatment and resolved spontaneously over several hours.

The paramedics responded and found the patient combative, cyanotic, incontinent of stool and urine, vomiting, salivating, and lacrimating excessively. He was bradycardic with a pulse rate of 50 beats per minute and a stable blood pressure. He was washed down, given 5 mg of atropine intravenously, and transported to a local hospital. On arrival his blood pressure was 155/ 122 mm Hg, with a pulse rate of 127 beats per minute, a respiratory rate of 20, and a temperature reading of 36.9°C. He was alert but mildly confused.

The patient’s clothes were removed and he was showered to remove any possible skin contamination. Gastric lavage was performed and 1 g/kg of body weight of activated charcoal with sorbitol was administered. Results of his initial laboratory studies were remarkable for a serum potassium concentration of 2.6 mmol/L, a serum carbon dioxide concentration of 19 mmol/L, and an anion gap of 19. Over a 2-hour period he received potassium supplements, 4 mg of atropine, and 1 g of pralidoxime intravenously prior to being transported to a tertiary facility.

ON ARRIVAL at the tertiary hospital his vital signs had normalized with a blood pressure of 130/100 mm Hg, a pulse rate of 90 beats per minute, a respiratory rate of 20, and a temperature of 34.8°C. He was alert but disoriented to time. His skin was diaphoretic and pale. He had pinpoint pupils, twitching of the eyelids, fasciculations of the facial muscles and tongue, bibasilar rales, and hypoactive bowel sounds. His neurologic examination revealed profound weakness and clonus that was greatest on the right side. He was able to lift his left arm against gravity but was limited to moving his fingers on the right side. Sensation and deep tendon reflexes were intact. Thiocyanate, tylenol, aspirin, iron, and lactate levels were within normal limits. Results of non-contrasted computed tomographic scan of the head and lumbar puncture were unremarkable.

After admission he became progressively weaker and had difficulty clearing his secretions. Arterial blood gases drawn 7 hours after admission demonstrated a pH of 7.32, a PCO2 of 32.9 mm Hg, and a PO2 of 72.1 mm Hg on 4 L/min of oxygen administered by nasal cannula. Owing to progressive worsening of the patient’s clinical status, he received a second treatment of 1 g of pralidoxime intravenously. Twenty minutes after the bolus of pralidoxime, and 10 hours after onset of his symptoms, he had a 3-minute tonic-clonic seizure that resolved spontaneously and was treated with 5 mg of diazepam intravenously. His condition continued to worsen, and 30 minutes later he was intubated after pretreatment with 80 mg of succinylcholine intravenously and thiopental intravenously for failure to maintain his airway. He was given two additional treatments of 1 g of pralidoxime intravenously over a 30- to 60-minute period within a 6-hour period followed by an infusion of 0.5 g per hour over a 40-hour time frame. His strength began to improve after the drip was initiated, more than 16 hours after the onset of his symptoms. He progressed from only moving his fingertips to moving his entire right arm and writing notes within 60 minutes of starting the infusion. The initial pralidoxime infusions were temporally associated with hypertensive episodes to as high as 195/100 mm Hg. The continu

Cholinesterase Concentrations*

Time (Hours)

Plasma

Red Blood Cell

02:00 (6)

469

16:30 (44)

3107

6.4

06:00 (58)

7287

04:00 (80)

7144

06:00 (130)

13.7

20:00 (168)

8719

11.5

22 days

8320

11.8

*Normal range, plasma (4499 to 13320 U/L), red blood cell (9.9 to 18.0 IU/mL).

Hours after the onset of symptoms.

ous infusion did not elevate his blood pressure.

Concurrent with the pralidoxime administration, the patient was given an additional 2 mg of atropine intravenously, followed by an atropine drip of 0.5 mg/h for 22 hours. During this time he became severely agitated and required sedation. The atropine was stopped. Fifteen hours later he was given 0.25 mg of glycopyrrolate mg per hour for 9 hours to control continued excess secretions while limiting central nervous system effects. He developed a temperature of 39°C, presumably from aspiration pneumonia, and was given 2 million units of penicillin per hour intravenously, 1 g of cefotaxime every 8 hours, and 1 g of vancomycin every 12 hours.

The RBC and plasma cholinesterase levels are presented in the Table. His initial plasma cholinesterase level 6 hours after onset of symptoms was 469 U/L (6% of normal) and did not increase to the normal range for another 52 hours. The initial RBC cholinesterase level 44 hours after admission was 6.4 U/mL (54% of normal). A repeated level 4 days later was 13.7 U/mL, and follow-up tests remained normal.

His condition gradually improved and he was extubated on the fifth day of hospitalization. After extubation, discussions with the patient and his family raised the possibility of poisoning with aldicarb (Temik). The earliest available blood

Page
559
Front Matter (R1-R12)
Executive Summary (1-4)
1 Introduction (5-13)
2 Curriculum Content (14-21)
3 Implementation Strategies (22-43)
4 Changing Medical Education (44-51)
5 Concluding Remarks (52-53)
References (54-58)
Appendixes (59-60)
A: Taking an Exposure History (61-96)
B: Medical School Courses and Clerkships: Access Points for Integrating Environmental Medicine (97-120)
C: Case Studies in Environmental Medicine (121-138)
Case Study 1: Arsenic Toxicity (139-163)
Case Study 2: Seasonal Arsenic Exposure from Burning Chromium-Copper-Arsenate-Treated Wood (164-167)
Case Study 3: Asbestos Toxicity (168-188)
Case Study 4: Benzene Toxicity (189-207)
Case Study 5: Beryllium Toxicity (208-223)
Case Study 6: Cadmium Toxicity (224-243)
Case Study 7: Fetal Death Due to Nonlethal Maternal Carbon Monoxide Poisoning (244-248)
Case Study 8: Carbon Tetrachloride Toxicity (249-266)
Case Study 9: Chlordane Toxicity (267-288)
Case Study 10: Chronic Reactive Airway Disease Following Acute Chlorine Gas Exposure in an Asymptomatic Atopic Patient (289-290)
Case Study 11: Chromium Toxicity (291-311)
Case Study 12: Cyanide Toxicity (312-331)
Case Study 13: Dioxin Toxicity (332-348)
Case Study 14: Ethylene/Propylene Glycol Toxicity (349-371)
Case Study 15: Formalin Asthma in Hospital Staff (372-373)
Case Study 16: Gasoline Toxicity (374-394)
Case Study 17: Hantavirus Pulmonary Syndrome: A Clinical Description of 17 Patients with a Newly Recognized Disease (395-401)
Case Study 18: Lead Poisoning from Mobilization of Bone Stores During Thyrotoxicosis (402-409)
Case Study 19: Lead Toxicity (410-435)
Case Study 20: Legionaires' Disease: Description of an Epidemic of Pneumonia (436-444)
Case Study 21: Mercury in House Paint as a Cause of Acrodynia: Effect of Therapy with N-Acetyl-D, L-Penixillamine (445-449)
Case Study 22: Mercury Toxicity (450-472)
Case Study 23: Methanol Toxicity (473-492)
Case Study 24: Methylene Chloride Toxicity (493-511)
Case Study 25: Paint Remover Hazard (512-515)
Case Study 26: Fatal Outcome of Methemoglobinemia in an Infant (516-517)
Case Study 27: Nitrate/Nitrite Toxicity (518-537)
Case Study 28: An Outbreak of Nitrogen Dioxide-Induced Respiratory Illness Among Ice Hockey Players (538-541)
Case Study 29: Pentachlorophenol Toxicity (542-557)
Case Study 30: Aldicarb Poisoning: A Case Report with Prolonged Cholinesterase Inhibition and Improvement After Pralidoxime Therapy (558-561)
Case Study 31: Cholinesterase-Inhibiting Pesticide Toxicity (562-584)
Case Study 32: Infertility in Male Pesticide Workers (585-587)
Case Study 33: Pesticide Food Poisoning from Contaminated Watermelons in California, 1985 (588-595)
Case Study 34: Poisoning of an Urban Family Due to Misapplication of Household Organophosphate and Carbamate Pesticides (596-604)
Case Study 35: Polynuclear Aromatic Hydrocarbon (PAH) Toxicity (605-621)
Case Study 36: Polychlorinated Biphenyl (PCB) Toxicity (622-638)
Case Study 37: Ionizing Radiation (639-673)
Case Study 38: Radon Toxicity (674-694)
Case Study 39: Residential Radon Exposure and Lung Cancer in Sweden (695-700)
Case Study 40: Community Oubreaks of Asthma Associated with Inhalation of Soybean Dust (701-706)
Case Study 41: Tetrachloroethylene Toxicity (707-726)
Case Study 42: Toluene Toxicity (727-743)
Case Study 43: Occupational Asthma Due to Toluene Diisocyanate Among Velcro-like Tape Manufacturers (744-749)
Case Study 44: 1,1,1-Trichloroethane (750-766)
Case Study 45: Trimethyltin Encephalopathy (767-771)
Case Study 46: Trichloroethylene Toxicity (772-792)
Case Study 47: Vinyl Chloride Toxicity (793-811)
Case Study 48: Work-Related Disorders of the Neck and Upper Extremity (812-813)
Case Study 49: Contact Dermatitis in Surgeons from Methylmethacrylate Bone Cement (814-816)
Case Study 50: Skin Lesions and Environmental Exposures: Rash Decisions (817-861)
Case Study 51: Acoustic Trauma Caused by the Telephone: A Report of Two Cases (862-867)
Case Study 52: Behavioral and Audiologic Manifestations of Noise-Induced Hearing Loss (868-871)
Case Study 53: Reproductive and Developmental Hazards (872-892)
Case Study 54: Childhood Asthma and Indoor Enviromental Risk Factors (893-903)
Case Study 55: Populations at Risk From Particulate Air Pollution - United States, 1992 (904-908)
D: Resources: Agencies, Organizations, Services, REferences, and Tables of Environmental Health Hazards (909-970)
E: Committee and Staff Biographies (971-975)